Inhibiting COX-2/PGE2 pathway with biodegradable NIR-Ⅱ fluorescent polymeric nanoparticles for enhanced photodynamic immunotherapy

Zhang, Xianghong; Hou, Hongyi; Wan, Jia; Yang, Jing; Tang, Dongsheng; Zhao, Dan; Liu, Tang; Shang, Kun

doi:10.1016/j.nantod.2023.101759

Cited by 13 publications

(5 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, tumor necrosis factor-𝛼 (TNF-𝛼) is a cytokine that can directly kill tumor cells without consequential toxicity to normal cells, and its increase can remarkably amplify the anti-tumor effect. [26] As expected, TNF-𝛼 was crucially increased in the tumor sections after synergistic therapy. The above results show that BSM has respectable biocompatibility and biosafety, can be applied to in vivo treatment, and its sono/photo-activated performance and promoted ICD powerfully reinforce the synergistic therapeutic effect.…”

Section: In Vivo Synergistic Therapysupporting

confidence: 66%

Topological Regulating Bismuth Nano‐Semiconductor for Immunogenic Cell Death‐Mediated Sonocatalytic Hyperthermia Therapy

Chen,

Yang,

et al. 2023

Small

View full text Add to dashboard Cite

Immunogenic cell death (ICD) can activate the body's immune system via dead cell antigens to achieve immunotherapy. Currently, small molecule drugs have been used for ICD treatment in clinical, however, how to precisely control the induced ICD while treating tumors is of great significance for improving therapeutic efficacy. Based on this, a sono/light dual response strategy to tumor therapy and activation of ICD is proposed. A topological synthesis method is used to obtain sulfur‐doped bismuth oxide Bi2O3−xSx (BS) using BiF3 (BF) as a template through reduction and a morphology‐controllable bismuth‐based nano‐semiconductor with a narrow bandgap is constructed. Under the stimulation of ultrasound, BS can produce reactive oxygen species (ROS) through the sonocatalytic process, which cooperates with BS to consume glutathione and enhance cellular oxidative damage, further inducing ICD. Due to the introduction of sulfur in the reduction reaction, BS can achieve photothermal conversion under light, and combine with ROS to treat tumors. Further, with the assistance of ivermectin (IVM) to form composite (BSM), combined with sono/light dual strategy, ICD is promoted and DCs maturation is accelerated. The proposed ICD‐mediated hyperthermia/sonocatalytic therapy strategy will pay the way for synergetic enhancement of tumor treatment efficacy and provide a feasible idea for controllable induction of ICD.

show abstract

Section: In Vivo Synergistic Therapysupporting

confidence: 66%

Topological Regulating Bismuth Nano‐Semiconductor for Immunogenic Cell Death‐Mediated Sonocatalytic Hyperthermia Therapy

Chen,

Yang,

et al. 2023

Small

View full text Add to dashboard Cite

show abstract

“…To this end, we designed a novel bis‐hydroxyl group containing BODIPY photosensitizer with a larger conjugated system, named MonoBodipy ( Figure A). [ 20 ] However, due to the extremely poor water solubility of MonoBodipy, it is difficult to directly apply it in vivo. In order to overcome this drawback, a polycondensation reaction was carried out by using the bis‐hydroxyl group containing MonoBodipy, a ROS‐sensitive monomer (2,2′‐(propane‐2,2‐diylbis(sulfanediyl))bis(ethan‐1‐ol), DSB) (Figure S1, Supporting Information) with two hydroxyl groups and 1,2,4,5‐cyclohexanetetracarboxylic dianhydride (HPMDA) at a molar feed ratio of 2:18:21.…”

Section: Resultsmentioning

confidence: 99%

A NIR‐II Fluorescent PolyBodipy Delivering Cationic Pt‐NHC with Type II Immunogenic Cell Death for Combined Chemotherapy and Photodynamic Immunotherapy

Wang

Tang

Karges

et al. 2023

Adv Funct Materials

Self Cite

View full text Add to dashboard Cite

Tumor immunotherapy has emerged as one of the most promising clinical techniques to treat cancer tumors. Despite its clinical application, the cancerous immunosuppressive microenvironment limits the therapeutic efficiency of the treatment. To generate a stronger immunogenic therapeutic effect, herein, a platinum complex for chemotherapy and a BODIPY photosensitizer for photodynamic therapy are encapsulated into multimodal type II immunogenic cell death (ICD) induce nanoparticles. As the platinum complex and the photosensitizer are able to induce type II ICD, an exceptionally strong immune response is observed in triple-negative breast cancer cells. While remaining stable and therefore poorly cytotoxic in the dark, the nanomaterial is found to quickly dissociate upon exposure to near-infrared light, causing a multimodal mechanism of action in cancer cells as well as multicellular tumor spheroids through combined chemotherapy, photodynamic therapy, and immunotherapy. The nanoparticles are found to nearly fully eradicate a triple-negative breast cancer tumor and therefore to strongly enhance the survival of tumor-bearing mice models using low drug and light doses.

show abstract

“…Inhibiting the COX-2/PGE 2 pathway can downregulate PD-L1 expression [25] and improve the immunosuppressive TME. [20,24] As a nonsteroidal anti-inflammatory drug, DA effectively inhibits COX-2 expression and PGE 2 release. [46] To confirm the in vitro effects of CCP@DA on COX-2/PEG 2 and PD-L1 (Figure 2A), we analyzed COX-2 expression in mouse breast cancer cells (4T1 cells) using western blotting (WB) assay and confocal laser scanning microscope (CLSM) (Figure 2B-D).…”

Section: In Vitro Cox-2 and Peg 2 Inhibitionmentioning

confidence: 99%

“…However, the released pro-tumor inflammatory factors such as interleukin-6 (IL-6), tumor necrosis factor-𝛼 (TNF-𝛼), [19][20][21] the upregulated cycoperoxidase-2 (COX-2), and COX-2 mediating prostaglandin E2 (PGE 2 ) [22,23] also cause detrimental inflammatory responses. [24,25] The resulting inflammatory microenvironment blocks dendritic cells (DCs) migration, [26,27] activates programmed death ligand 1 (PD-L1) upregulation, [28,29] and recruits immunosuppressive cells [30][31][32] to promote an immunosuppressive microenvironment. [33] Suppressing phototherapy-induced detrimental inflammation while maintaining an immune-promoting inflammatory response is a Scheme 1.…”

Section: Introductionmentioning

confidence: 99%

“…[28,36,37] COX-2 inhibitor loaded nanodrugs reduce inflammation and stimulate immune response in cancer therapy. [24,25,38] To further suppress detrimental inflammation post phototherapy while enhancing the anti-tumor immune response, the CCP was coassembled with diclofenac (DA), a nonsteroidal anti-inflammatory drug, to form the self-delivery nanodrug CCP@DA (Scheme 1). In addition to inducing potent ICD, CCP could downregulate the PD-L1 expressionin tumor cells by directly destroying the cell membrane.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A Self‐Delivery Nanodrug Simultaneously Inhibits COX‐2/PGE₂ Mediated Inflammation and Downregulates PD‐L1 to Boost Photoimmunotherapy

Lai,

Chen,

Shi

et al. 2024

Adv Healthcare Materials

View full text Add to dashboard Cite

Phototherapy promotes anti‐tumor immunity by inducing immunogenic cell death (ICD), However, the accompanying inflammatory responses also trigger immunosuppression, attenuating the efficacy of photo‐immunotherapy. Herein, they co‐assembled a cell‐membrane targeting chimeric peptide C16‐Cypate‐RRKK‐PEG8‐COOH (CCP) and anti‐inflammatory diclofenac (DA) to develop a nanodrug (CCP@DA) that both enhances the immune effect of phototherapy and weakens the inflammation‐mediated immunosuppression. CCP@DA achieves cell membrane‐targeting photodynamic and photothermal synergistic therapies to damage programmed death ligand 1 (PD‐L1) and induce a strong ICD to activate anti‐tumor response. Simultaneously, the released DA inhibits the cycoperoxidase‐2 (COX‐2)/prostaglandin E2 (PGE2) pathway in tumor cells to inhibit pro‐tumor inflammation and further down‐regulate PD‐L1 expression to relieve the immunosuppressive microenvironment. CCP@DA significantly inhibited tumor growth and inflammation both in vitro and in vivo, while maintaining a potent anti‐tumor immune response. Additionally, it exhibits excellent anti‐metastatic capabilities and prolongs mouse survival time with a single dose and low levels of near‐infrared (NIR) light exposure. This work provides a valuable strategy to control the therapy‐induced inflammation for high‐efficiency photoimmunotherapy.

show abstract

Inhibiting COX-2/PGE2 pathway with biodegradable NIR-Ⅱ fluorescent polymeric nanoparticles for enhanced photodynamic immunotherapy

Cited by 13 publications

References 44 publications

Topological Regulating Bismuth Nano‐Semiconductor for Immunogenic Cell Death‐Mediated Sonocatalytic Hyperthermia Therapy

Topological Regulating Bismuth Nano‐Semiconductor for Immunogenic Cell Death‐Mediated Sonocatalytic Hyperthermia Therapy

A NIR‐II Fluorescent PolyBodipy Delivering Cationic Pt‐NHC with Type II Immunogenic Cell Death for Combined Chemotherapy and Photodynamic Immunotherapy

A Self‐Delivery Nanodrug Simultaneously Inhibits COX‐2/PGE₂ Mediated Inflammation and Downregulates PD‐L1 to Boost Photoimmunotherapy

Contact Info

Product

Resources

About

Inhibiting COX-2/PGE2 pathway with biodegradable NIR-Ⅱ fluorescent polymeric nanoparticles for enhanced photodynamic immunotherapy

Cited by 13 publications

References 44 publications

Topological Regulating Bismuth Nano‐Semiconductor for Immunogenic Cell Death‐Mediated Sonocatalytic Hyperthermia Therapy

Topological Regulating Bismuth Nano‐Semiconductor for Immunogenic Cell Death‐Mediated Sonocatalytic Hyperthermia Therapy

A NIR‐II Fluorescent PolyBodipy Delivering Cationic Pt‐NHC with Type II Immunogenic Cell Death for Combined Chemotherapy and Photodynamic Immunotherapy

A Self‐Delivery Nanodrug Simultaneously Inhibits COX‐2/PGE2 Mediated Inflammation and Downregulates PD‐L1 to Boost Photoimmunotherapy

Contact Info

Product

Resources

About

A Self‐Delivery Nanodrug Simultaneously Inhibits COX‐2/PGE₂ Mediated Inflammation and Downregulates PD‐L1 to Boost Photoimmunotherapy